Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients
- PMID: 33496632
- PMCID: PMC7524453
- DOI: 10.1152/ajplung.00262.2020
Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients
Conflict of interest statement
K. Sriram has no conflicts of interest, financial or otherwise, to declare. P. A. Insel is not currently but within the past 3 years has served as a consultant or received research support from Merck, Pfizer, and Bristol Myers Squibb.
Comment on
-
Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection.Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1016-L1019. doi: 10.1152/ajplung.00136.2020. Epub 2020 Apr 8. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 32266822 Free PMC article. No abstract available.
References
-
- Centers for Disease Control and Prevention Provisional death counts for coronavirus disease (covid-19) (Online). https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm [20 May, 2020].
-
- Sparks MA, Hiremath S. The Coronavirus Conundrum: ACE2 and Hypertension Edition (Online). NephJC. https://www.nephjc.com/news/covidace2 [4 May, 2020].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
